Ratings Apollomics, Inc.

Equities

APLM

KYG0411D1079

Market Closed - Nasdaq Other stock markets 21:30:00 17/05/2024 BST			5-day change	1st Jan Change
0.3322 ^USD	-2.29%		-10.67%	-65.58%

05-08	Apollomics, Inc. Appoints Robert Lin to the Board of Directors	CI
05-08	Apollomics, Inc. announced that it has received $5.75 million in funding	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
APOLLOMICS, INC.	-65.58%	36.1M	-
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B	B+
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B	B+
ARGENX SE	-2.39%	21.96B	B
BIONTECH SE	-14.15%	21.87B	B+
GENMAB A/S	-5.29%	19.21B	A-
BEIGENE, LTD.	-4.16%	18.08B	B
WUXI APPTEC CO., LTD.	-38.29%	17.71B	A-
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B	C+
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes